Otic Pharma in deal to become Tokai's majority owner

23 December 2016

After announcing back in September that it had initiated a review of strategic alternatives for the company, US biotech firm Tokai Pharmaceuticals (Nasdaq: TKAI) has now entered into transaction, with the news pushing its share 19.8% higher to $1.21 by close of trading on Thursday

Tokai and Otic Pharma, a privately-held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose and throat, together with the shareholders of Otic Pharma, have entered into a definitive share purchase agreement under which the shareholders of Otic will become the majority owners of Tokai.

The transaction will result in a Nasdaq-listed company focused on the development and commercialization of products for ENT disorders, including Otic Pharma’s lead candidate which is a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK